哈尔滨医科大学学报
哈爾濱醫科大學學報
합이빈의과대학학보
JOURNAL OF HARBIN MEDICAL UNIVERSITY
2009年
2期
194-196
,共3页
肿瘤标志物%非小细胞肺癌%阳性检出率
腫瘤標誌物%非小細胞肺癌%暘性檢齣率
종류표지물%비소세포폐암%양성검출솔
tumor marker%non-small cell lung cancer%positive findings
目的 探讨联合检测CYFRA21-1、CA125、CEA对非小细胞肺癌的临床应用价值.方法 研究对象为我院2004年6月至2008年6月由病理证实的非小细胞肺癌患者165例,测定其血清CYFRA21-1、CA125、CEA值.结果 CYFRA21-1在鳞癌中阳性率最高为54.55%(30/55);CA125、CEA在腺癌中阳性率最高,分别为58.59%(58/99)、52.53%(52/99).三项联合检测总阳性率明显升高为81.82%(135/165),其中Ⅲ期和Ⅳ期非小细胞肺癌的阳性检出率分别为89.13%(41/46)、86.52%(77/89),均高于I期和Ⅱ期的阳性检出率.结论 联合检测CYFRA21-1、CA125和CEA可起到互补作用,从而明显提高非小细胞肺癌的阳性检出率,且肿瘤的阳性检出率随病情的进展而升高.
目的 探討聯閤檢測CYFRA21-1、CA125、CEA對非小細胞肺癌的臨床應用價值.方法 研究對象為我院2004年6月至2008年6月由病理證實的非小細胞肺癌患者165例,測定其血清CYFRA21-1、CA125、CEA值.結果 CYFRA21-1在鱗癌中暘性率最高為54.55%(30/55);CA125、CEA在腺癌中暘性率最高,分彆為58.59%(58/99)、52.53%(52/99).三項聯閤檢測總暘性率明顯升高為81.82%(135/165),其中Ⅲ期和Ⅳ期非小細胞肺癌的暘性檢齣率分彆為89.13%(41/46)、86.52%(77/89),均高于I期和Ⅱ期的暘性檢齣率.結論 聯閤檢測CYFRA21-1、CA125和CEA可起到互補作用,從而明顯提高非小細胞肺癌的暘性檢齣率,且腫瘤的暘性檢齣率隨病情的進展而升高.
목적 탐토연합검측CYFRA21-1、CA125、CEA대비소세포폐암적림상응용개치.방법 연구대상위아원2004년6월지2008년6월유병리증실적비소세포폐암환자165례,측정기혈청CYFRA21-1、CA125、CEA치.결과 CYFRA21-1재린암중양성솔최고위54.55%(30/55);CA125、CEA재선암중양성솔최고,분별위58.59%(58/99)、52.53%(52/99).삼항연합검측총양성솔명현승고위81.82%(135/165),기중Ⅲ기화Ⅳ기비소세포폐암적양성검출솔분별위89.13%(41/46)、86.52%(77/89),균고우I기화Ⅱ기적양성검출솔.결론 연합검측CYFRA21-1、CA125화CEA가기도호보작용,종이명현제고비소세포폐암적양성검출솔,차종류적양성검출솔수병정적진전이승고.
Objective To investigate the clinical significance of combined detection of CYFRA21-1, CA125 and CEA in non-small cell lung cancer(NSCLC). Methods One hundred and sixty-five patients with pathologically proven NSCLC as the subjects were analyzed by measuring the levels of above three markers in serum in the period from June 2004 to June 2008. Results The highest positive rate of CYFRA21-1, 54.55% (30/55) was found in the patients with squamous carcinoma, while the positive rate of CA125 and CEA in adenocarcinoma was 58. 5% (58/99) and 52. 53% (52/99) ,respectively, each was higher than that of CYFRA21-1. The total positive rate was 81. 82% (135/165) , obviously higher than that of any single marker. The total rates of positive findings of NSCLC in stages III and IV were 89. 13% (41/46) and 86. 52 (77/89) ,respectively, each total rate was very significantly higher than stage I and stage II. Conclusion Combined use of CYFRA21-1, CA125 and CEA measurement may play a complementary role and evidently raise the detection rate of NSCLC in comparison with use of any single marker. In addition, the rate of positive findings was found to increase with development of the disease.
